治疗缺血性心脏病的化疗法:一个随机对照试验
Merril L Knudtson1, D George Wyse, P Diane Galbraith
1Foothills Medical Center, 1403 29th St NW, Calgary, Alberta, Canada T2N 2T9. knudtson@shaw.ca
JAMA
|February 2, 2002
概括
使用乙烯基胺三酸 (EDTA) 的化疗法没有改善稳定缺血性心脏病患者的运动缺血门或生活质量. 与安慰剂相比,这种随机试验没有发现任何显著的益处.
科学领域:
- 心脏病学 心脏病学
- 替代医学研究 替代医学研究
- 临床试验 临床试验
背景情况:
- 使用EDTA的化疗法是一种流行的,但尚未证明的缺血性心脏病的替代治疗方法.
- 它在改善患者结果方面的有效性仍然存在争议.
研究的目的:
- 评估EDTA化疗对稳定缺血性心脏病患者的运动缺血门和生活质量的影响.
- 确定当前的EDTA协议是否提供了有利的效果.
主要方法:
- 进行了一项双盲,随机,安慰剂对照试验,其中84名患者被诊断患有冠状动脉疾病或心肌梗塞和稳定性 angina.
- 参与者接受了体重调整的EDTA化疗法或安慰剂,每周两次,持续15周,随后每月治疗3个月.
- 主要结局指标是27周随访后在跑步机测试中时间变化到1毫米的ST抑郁.
主要成果:
- 无论是EDTA化组还是安慰剂组,运动时间到缺血的改善都相似 (63秒与54秒).
- 两组之间没有观察到统计学上显著的差异 (9秒的差异;P =.69).
- 在两个治疗臂中,运动能力和生活质量得分的改善是可比的.
结论:
- 该研究没有发现证据支持使用EDTA化疗法来改善稳定缺血性心脏病患者的运动耐受性或生活质量.
- 结果表明,EDTA化疗对于这种患者群体来说并不比安慰剂更有效.
相关概念视频
Ischemic Heart Disease: Overview
3.8K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.8K
Coronary Artery Disease IV: Preventive Measures
890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Coronary Artery Disease V: Interprofessional Care
444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Acute Coronary Syndrome III: Diagnostic Studies
495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Acute Coronary Syndrome IV: Interprofessional Care
522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741


